[ad_1]
According to new research, protection against serious illness from so-called innate immunity remains superior to the protection provided by the COVID-19 vaccine.
Researchers in Qatar have found that those who survived the COVID-19 infection and were not vaccinated had very high protection against severe or deadly COVID-19.
“The efficacy of the primary infection against severe, serious, or fatal COVID-19 reinfection was 97.3%, regardless of the primary or reinfection variant, with no evidence of decline. Similar results. It was also seen in a subgroup analysis of people over the age of 50, “said Dr. Laith Abu-Raddad and colleagues at Weill Cornell Medicine-Qatar after studying long-term natural immunity in unvaccinated people.
According to other studies and actual data, the percentage is higher than the protection from the COVID-19 vaccine.
For example, Swedish researchers Found in may Two doses of the vaccine were only 54% effective against the Omicron variant of the CCP (Chinese Communist Party) virus that causes COVID-19.
Meanwhile, South African scientists found The efficacy of the AstraZeneca and Pfizer vaccines peaked at 88% and quickly dropped to less than 70%.
A group of Qatar discovered innate immunity over 14 months after the person’s first infection. “Regardless of the mutation, there is no evidence of weakness and it remains very strong.”
This study was published prior to peer review On the website medRxiv..
Many have eventually been vaccinated with the COVID-19 vaccine, and few researchers have long-term studies of the innate immunity of unvaccinated people.
Vaccines, on the other hand, decline over time for both infections and serious illnesses, triggering booster dose recommendations, and some Americans even take five doses within 10 months. I have.
Innate immunity works poorly against reinfection
Vaccines were once said to provide nearly 100 percent protection against symptomatic treatment. They now provide less than 50 percent protection against short-term infections, even after booster administration, following the advent of Omicron.
The strain and its subvarieties predominate in countries around the world, including the United States and Qatar.
Innate immunity was thought to provide strong protection against reinfection. However, Qatar researchers have found that it also provides inadequate protection against reinfection from Omicron.
Studies show that pre-Omicron infections were as high as 90.5% for pre-Omicron reinfections and remained at about 70% by 16 months. However, pre-Omicron infection against Omicron reinfection was only 38% effective, higher in those infected with the original Wuhan or Delta variant and lower in those sick with the Alpha or Beta strains.
Modeling showed that protection dropped to zero percent by 18 months, but the shield still seems to last longer than the vaccine, the researchers said.
“Vaccine immunity to Omicron subvariants lasts less than 6 months, but pre-Omicron innate immunity can last a little over a year, assuming Gompelz collapse,” they write.
Limitations of the study included differences in test frequency between the cohorts studied and depletion of the group with COVID-19 infection due to death.
[ad_2]